Table 2.
Baseline CD4+ count in cells/μL, n (%)
|
|||
---|---|---|---|
200–349 | 350–499 | ≥500 | |
Twelve months after initiating ART (n = 26,742) | |||
Number of treatment nonretentions | 3896 (18%) | 927 (21%) | 366 (23%) |
Number retained on treatment at study end-point | 20,821 | 4333 | 1588 |
Unadjusted OR (95% CI), p-value | 0.77 (0.68–0.87), <0.0001 | 0.91 (0.79–1.04), 0.17 | 1 |
OR adjusted by age and sex (95% CI), p-value | 0.76 (0.67–0.86), <0.0001 | 0.91 (0.79–1.04), 0.17 | 1 |
OR adjusted by age, sex and transmission mode (95% CI), p-value | 0.89 (0.78–1.01), 0.063 | 0.98 (0.85–1.12), 0.74 | 1 |
OR adjusted by age, sex, and marital status (95% CI), p-value | 0.75 (0.66–0.85), <0.0001 | 0.91 (0.79–1.04), 0.16 | 1 |
OR adjusted by all factorsa but not transmission mode (95% CI), p-value | 0.77 (0.68–0.87), <0.0001 | 0.92 (0.80–1.05), 0.22 | 1 |
OR adjusted by all factorsa and transmission mode (95% CI), p-value | 0.85 (0.75–0.96), 0.011 | 0.96 (0.83–1.10), 0.53 | 1 |
Twenty-four months after initiating ART (n = 24,274) | |||
Number of treatment nonretentions | 2283 (12%) | 524 (13%) | 203 (14%) |
Number retained on treatment at study end-point | 18,921 | 3938 | 1415 |
Unadjusted OR (95% CI), p-value | 0.82 (0.70–0.96), 0.012 | 0.82 (0.77–1.10), 0.33 | 1 |
OR adjusted by age and sex (95% CI), p-value | 0.81 (0.69–1.09), 0.008 | 0.92 (0.77–1.09), 0.33 | 1 |
OR adjusted by age, sex, and transmission mode (95% CI), p-value | 0.98 (0.84–1.15), 0.80 | 0.99 (0.83–1.19), 0.95 | 1 |
OR adjusted by age, sex and marital status (95% CI), p-value | 0.80 (0.68–0.94), 0.0053 | 0.92 (0.77–1.10), 0.35 | 1 |
OR adjusted by all factorsa but not transmission mode (95% CI), p-value | 0.87 (0.74–1.02), 0.08 | 0.96 (0.81–1.15), 0.66 | 1 |
OR adjusted by all factorsa and transmission mode (95% CI), p-value | 0.98 (0.83–1.15), 0.81 | 1.01 (0.84–1.20), 0.95 | 1 |
All factors here include sex, age, marital status, type of treatment center, initial ART regimen.
ART, antiretroviral therapy; CI, confidence interval; OR, odds ratio.